Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors

Дата публикации: 08-07-2026 00:07:53

BOTHELL, Wash. July 8, 2026 – Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the U.S. Food and Drug Administration (FDA or the...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors	0	11.39	29-04-2026
2	U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma	0	6.44	13-07-2026
3	Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer	0	14.56	22-07-2026
4	Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma	0	16.87	26-06-2026
5	Oncolytics Biotech Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer	0	17.15	20-07-2026
6	BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Ovarian Cancer	0	13.23	07-08-2026
7	New Drug Application for Neladalkib in TKI Pre-Treated Advanced ALK-Positive NSCLC Accepted for Filing with Priority Review by the FDA	0	17.4	27-05-2026
8	Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks	0	17.66	06-07-2026
9	FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting	0	11.63	01-06-2026
10	Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study	0	10.39	22-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 13.2. Источник: www.drugs.com.